MET and non-small cell lung carcinoma: Given the promising responses in patients treated with MET inhibitors in some clinical trials, the Japanese Ministry of Health, US FDA, and China National Medical Products Administration approved tepotinib, capmatinib, and savolitinib for the treatment of NSCLC with MET dysregulation in 2020.